

SOUTHERN DISTRICT HEALTH REGION ADOPTS PACIFIC EDGE'S CXBLADDER TESTS

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces it has substantially completed a commercial agreement with the Southern District Health Region (SDHR) for the use of its non-invasive Cxbladder genomic biomarker tests.

The SDHR, which under the new Te Whatu Ora, Health New Zealand, has assumed administrative healthcare responsibility for 326,000 people across Otago and Southland, will deploy Cxbladder Triage into the primary care setting. Deploying into primary care follows the clinical practice model for hematuria evaluation (blood in the urine) established in the Canterbury health region. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.

The agreement with SDHR will mean that 15 of New Zealand's 20 administrative health regions, which together cover more than 75% of the country's population, will now have access to the test via public healthcare. Under the primary care model, General Practitioners will be able to order Cxbladder Triage to help safely de-intensify clinical workup for patients presenting with hematuria. In many cases this will reduce the need for secondary referral and an invasive cystoscopy.

Brent Pownall, VP Commercial for the Asia Pacific region at Pacific Edge, said: "We are delighted to be deploying Cxbladder in the Southern region – the home of Pacific Edge where Cxbladder was conceived and developed. Adoption of Cxbladder Triage at SDHR in the primary care model is further affirmation of the clinical utility of Cxbladder for de-intensifying hematuria evaluation at the earliest point in the patient care pathway and a great example of the strength and capability of Otago's healthcare research community.

"Cxbladder can safely de-intensify clinical workup, which optimizes available public healthcare funding and frees up healthcare resources for those patients most in need. An important benefit for patients is that it can safely spare patients from the potential risks and discomfort of an invasive cystoscopy examination, meaning Cxbladder is a positive change in the standard of patient care."

The Southern region is one of the largest in the country, covering 62,000 sq km. Cxbladder sample collection will be available via Southern Community Labs sites and GP offices. Meanwhile, in hard-to-reach rural areas patients will be able to use Pacific Edge's in-home sampling system.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263

Coran Lill
The Project
+64 27 342 3836

OVERVIEW www.pacificedge.co.nz www.pacificedgeidx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com

Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.